Alphabet's AI Drug Discovery Firm Isomorphic Labs in Funding Talks at Valuation of at Least $40 Billion

Just five months after its $2.1 billion funding round, the company has reopened negotiations, with a potential valuation of up to $50 billion. Spun out of DeepMind and built on the core AlphaFold technology, it has partnered with top pharmaceutical companies such as Eli Lilly and Novartis, focusing on cancer and immune disease therapies. Although no AI-driven drug has yet reached the market, capital continues to bet on its disruptive potential to compress drug development timelines from years to months.